AltruBio
PrivateLast Round
Series B
May 21, 2024
Total Funding Raised
$288M
Company Overview
AltruBio operates in Healthcare & Life Sciences and is based in San Francisco, California. Its latest recorded funding round was a Series B round in May 2024.
AltruBio is a clinical-stage biotechnology company that develops novel antibody therapeutics for immunological and inflammatory diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
AltruBio Comparables
Compare AltruBio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Allianthera (Suzhou) Biopharmaceuticals Co., Ltd. | 78% | |
| Athos Therapeutics | 77% | |
| AnaptysBio, Inc. | 77% |
For institutional investors. Book with your work email.
AltruBio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | May 21, 2024 | ||||
| Series A | Apr 15, 2021 | ||||
| VC Round | Aug 15, 2014 | ||||
| VC Round | Jun 22, 2012 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
AltruBio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Soleus Capital | Series B |
| RA Capital Management | Series B |
| CAM Capital | Series A |
| aMoon | Series B, Series A |
| BVF Partners L.P. | Series A |
| Blackstone Multi-Asset Investing | Series B |
| Blackstone Funds | Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- May 21, 2024
$225M round with participation from Blackstone Funds and aMoon.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventOct 23, 2026
AltruBio presents the latest ALTB-268 clinical data at European Digestive Disease Week (UEG Week 2026) in 2026.
- attends_eventOct 7, 2026
AltruBio presents new data from its ALTB-268 Phase 2a ASCEND UC2a trial in ulcerative colitis at United European Gastroenterology (UEG) Week 2026 in Spain on Oct 20th '26.
For institutional investors. Book with your work email.
AltruBio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about AltruBio's valuation, stock price, and market status.
Is AltruBio a public or private company?
AltruBio is a private company.
What is the current stock price of AltruBio?
AltruBio is a private company, so its shares have no public market price. Caplight tracks AltruBio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is AltruBio worth (valuation)?
Valuation information for AltruBio is not publicly available.
Can I buy AltruBio stock?
AltruBio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was AltruBio's last funding round?
AltruBio's most recent funding round was Series B on May 21, 2024.
Who are the main investors in AltruBio?
Key investors in AltruBio include aMoon.
Will AltruBio IPO soon?
No public IPO plans have been announced for AltruBio.
How can I track AltruBio secondary market activity?
Caplight tracks bids, offers, and trades in AltruBio's shares on secondary markets.